A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Active, not recruiting · Phase 1 · NCT06607185
Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
At a glance
- Research payments reported, 2025
- $1.6M
- U.S. investigators named
- 22
- Sites paid
- 21
- Planned or actual enrollment
- 750
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY4066434. (drug), Cetuximab (drug), Nab paclitaxel (drug), Gemcitabine (drug), Oxaliplatin (drug), Leucovorin (drug), Irinotecan (drug), 5Fluorouracil (drug), Carboplatin (drug), Cisplatin (drug), Pemetrexed (drug), Pembrolizumab (drug)
- Dates
- Started 2024-10-21; completion 2030-01
- Results posted
- Not yet
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.
From ClinicalTrials.gov, last updated 2026-07-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1.6M in research payments for this study in 2025 (22 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Tanios S. Bekaii-saab, M.D. Hematology & Oncology · Scottsdale, AZ
- Edward B. Garon, MD Hematology & Oncology · Los Angeles, CA
- Aditya V. Shreenivas, MD Medical Oncology · Duarte, CA
- Vivek Subbiah, MD Medical Oncology · Stanford, CA
- Michael Cecchini, MD Hematology & Oncology · New Haven, CT
- Aakash Desai, MBBS Hematology & Oncology · Farmington, CT
- John H. Strickler, MD Hematology & Oncology · Jacksonville, FL
- Ardaman Shergill Medical Oncology · Chicago, IL
- Gregory A. Durm, MD Hematology & Oncology · Indianapolis, IN
- Brandon M. Huffman, M.D. Hematology & Oncology · Boston, MA
- Aparna R. Parikh, M.D. Medical Oncology · Boston, MA
- Shirish M. Gadgeel, MD Medical Oncology · Detroit, MI
- Nehal J. Lakhani, M.D. Hematology & Oncology · Grand Rapids, MI
- Benjamin O. Herzberg, MD Medical Oncology · New York, NY
- Rona Yaeger, M.D. Medical Oncology · New York, NY
- Dale R. Shepard, M.D., PH.D. Hematology & Oncology · Cleveland, OH
- Janie Y. Zhang, MD Medical Oncology · Pittsburgh, PA
- David S. Hong, M.D. Medical Oncology · Houston, TX
- Syed M. Kazmi, M.D. Hematology & Oncology · Dallas, TX
- Amita Patnaik, M.D. Medical Oncology · San Antonio, TX
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
- Siddhartha H. Devarakonda, MD Medical Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana Farber PArtners Cancer Care Inc $176,280
- South Texas Accelerated Research Therapeutics LLC $142,777
- Sarah Cannon Research Institute LLC $122,263
- Memorial Sloan-Kettering $118,943
- Start Ctr for Cancer Care $115,816
- Fairfax-Northern Virginia $108,759
- Ut MD Anderson Cancer Center $106,336
- Trustees of Columbia Univ in The City of Ny $90,434
- Indiana University $75,044
- Duke University $74,102
- Cleveland Clinic, OH $68,111
- The University of Texas $56,003
- City of Hope National Medical Ctr $53,012
- Ronald Reagan UCLA Medical Center, CA $51,656
- University of Alabama Hospital, AL $46,540
- Henry Ford Health Hospital, MI $43,170
- Yale University $39,002
- University of Chicago $38,758
- Univ of Pittsburgh Cancer Institute Cancer Srvcs $36,800
- Mayo Clinic Hospital, AZ $36,360
- Swedish Issaquah, WA $33,800
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.